Breaking News, Financial News

Financial Report: Genzyme 4Q

Genetic Diseases revenue was $315.1 million in the quarter (-44%) due to product supply interruption.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme 4Q 4Q Revenues: $1.1 billion (-8%) 4Q Earnings: $23.2 million (earnings were $86.7 million in 4Q08) FY Revenues: $4.5 billion (-2%) FY Revenues: $422.3 million (flat) Comments: Genetic Diseases revenue was $315.1 million in the quarter (-44%) due to product supply interruption. Cerezyme sales were $105.4 million (-66%), and Fabrazyme sales were down 54% to $58.0 million. Cardiometabolic and Renal sales in the quarter were $259.2 million (+7%). Renagel and Renvela sales wer...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters